Interleukin Antibody

MT204 is a humanized IgG1 antibody inhibitor that targets IL-2 from human and rhesus monkey sources. It prevents soluble IL-2 from binding to the intermediate-affinity IL-2 receptor and blocks IL-2 bound to CD25 from interacting with the high-affinity IL-2 receptor. In rhesus monkey allogeneic skin transplant models, MT204 shows excellent tolerability and potent immunosuppressive activity. With linear pharmacokinetics, a reasonable serum half-life, and signs of good safety and efficacy, MT204 holds promise for use in immunotherapy.